{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tiotropium+bromide&page=2",
    "query": {
      "intervention": "Tiotropium bromide",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tiotropium+bromide&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T14:27:19.324Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00846586",
      "title": "Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Indacaterol 150 μg",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium 18 μg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to indacaterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1134,
      "start_date": "2009-03",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2011-08-18",
      "last_synced_at": "2026-09-29T14:27:19.324Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00846586"
    },
    {
      "nct_id": "NCT03478696",
      "title": "A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "budesonide/formoterol",
          "type": "DRUG"
        },
        {
          "name": "albuterol/salbutamol",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match budesonide/formoterol",
          "type": "DRUG"
        },
        {
          "name": "tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "placebo to match tiotropium",
          "type": "DRUG"
        },
        {
          "name": "ELLIPTA",
          "type": "DEVICE"
        },
        {
          "name": "MDI",
          "type": "DEVICE"
        },
        {
          "name": "HandiHaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 732,
      "start_date": "2018-06-25",
      "completion_date": "2019-03-18",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-09-29T14:27:19.324Z",
      "location_count": 42,
      "location_summary": "Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03478696"
    },
    {
      "nct_id": "NCT05986591",
      "title": "Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Test Product - Tiotropium Bromide Inhalation Powder 18 mcg",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Spiriva Handihaler (Tiotropium Bromide) 18 mcg",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Xiromed LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 335,
      "start_date": "2022-08-17",
      "completion_date": "2023-08-14",
      "has_results": false,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-09-29T14:27:19.324Z",
      "location_count": 24,
      "location_summary": "Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05986591"
    },
    {
      "nct_id": "NCT03964220",
      "title": "Impact of Tiotropium Add-on Therapy in Patients With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Tiotropium Respimat®",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Corticosteroid/Long-acting beta-agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 7857,
      "start_date": "2019-03-15",
      "completion_date": "2019-09-20",
      "has_results": true,
      "last_update_posted_date": "2020-11-03",
      "last_synced_at": "2026-09-29T14:27:19.324Z",
      "location_count": 1,
      "location_summary": "White Plains, New York",
      "locations": [
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03964220"
    },
    {
      "nct_id": "NCT01225913",
      "title": "Mechanism(s) of Airflow Limitation During Exacerbation of Asthma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "fluticasone/salmeterol in all asthmatics",
          "type": "DRUG"
        },
        {
          "name": "budesonide/formoterol or fluticasone/salmeterol in all asthmatics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gelb, Arthur F., M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "10 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2007-10",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2023-10-26",
      "last_synced_at": "2026-09-29T14:27:19.324Z",
      "location_count": 1,
      "location_summary": "Lakewood, California",
      "locations": [
        {
          "city": "Lakewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01225913"
    },
    {
      "nct_id": "NCT00772538",
      "title": "Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "tiotropium 5mcg/day",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 459,
      "start_date": "2008-10",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-08-18",
      "last_synced_at": "2026-09-29T14:27:19.324Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Riverside, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00772538"
    },
    {
      "nct_id": "NCT05501639",
      "title": "Exacerbation Risk in Asthma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "tiotropium",
          "type": "DRUG"
        },
        {
          "name": "long-acting β2-agonists (LABA)",
          "type": "DRUG"
        },
        {
          "name": "inhaled corticosteroids (ICS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1899,
      "start_date": "2021-05-14",
      "completion_date": "2021-11-02",
      "has_results": true,
      "last_update_posted_date": "2024-04-01",
      "last_synced_at": "2026-09-29T14:27:19.324Z",
      "location_count": 1,
      "location_summary": "White Plains, New York",
      "locations": [
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05501639"
    },
    {
      "nct_id": "NCT02796677",
      "title": "AMPLIFY - D6571C00001 Duaklir USA Phase III Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)",
          "type": "DRUG"
        },
        {
          "name": "Aclidinium bromide 400 μg (AB 400 μg)",
          "type": "DRUG"
        },
        {
          "name": "Formoterol fumarate 12 μg (FF 12 μg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg",
          "type": "OTHER"
        },
        {
          "name": "Tiotropium 18 μg (TIO 18 μg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to TIO 18 μg",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "40 Years to 130 Years"
      },
      "enrollment_count": 1595,
      "start_date": "2016-07-05",
      "completion_date": "2017-06-08",
      "has_results": true,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-09-29T14:27:19.324Z",
      "location_count": 85,
      "location_summary": "Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more",
      "locations": [
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02796677"
    },
    {
      "nct_id": "NCT00668772",
      "title": "Tiotropium/Salmeterol Inhalation Powder in COPD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Tiotropium/Salmeterol",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2008-04-15",
      "completion_date": "2008-11-21",
      "has_results": true,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-09-29T14:27:19.324Z",
      "location_count": 16,
      "location_summary": "Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00668772"
    },
    {
      "nct_id": "NCT05179512",
      "title": "Replication of the INSPIRE Trial in Healthcare Claims Data",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "salmeterol-fluticasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 98278,
      "start_date": "2020-09-22",
      "completion_date": "2021-08-30",
      "has_results": false,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-09-29T14:27:19.324Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05179512"
    }
  ]
}